Education Archive

PATRICIA HPV vaccine trial final report

This week The Lancet reports the final results of the worlds largest trial of a cervical cancer vaccine - PApilloma TRIal against Cancer In young Adults (PATRICIA). The study, involving 18,644 women, confirmed that Cervarix is highly effective at protecting against the two most common cervical cancer-causing HPV types, 16 and 18. The study also showed that the vaccine provides cross-protection against HPV types 31, 33 and 45. and effectively protects against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types.